Gene expression profile of serial samples of transformed B-cell lymphomas

Laboratory Investigation

Volumn 83, Issue 2, 2003, Pages 271-285

  De Vos, Sven ^a,b,g   Hofmann, Wolf Karsten ^b   Grogan, Thomas M ^e   Krug, Utz ^b   Schrage, Mathew ^a   Miller, Thomas P ^f   Braun, Jonathan G ^a   Wachsman, William ^c,d   Koeffler, H Phillip ^b   Said, Jonathan W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON REGULATORY FACTOR 4; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CELL TRANSFORMATION; CHROMOSOME DAMAGE; CLINICAL ARTICLE; DNA MICROARRAY; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

EID: 0037324949     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000053913.85892.E9     Document Type: Article

References (69)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM, et al (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
2. Aventin A, Mecucci C, Guanyabens C, Brunet S, Soler J, Bordes R, and Hvan den Berghe (1990). Variant t(2;18) translocation in a Burkitt conversion of follicular lymphoma. Br J Haematol 74:367-369.
3. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, Bryon PA, and Coiffier B (1997). Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594.
4. Bentz M, Werner CA, Dohner H, Joos S, Barth TF, Siebert R, Schroder M, Stilgenbauer S, Fischer K, Moller P, and Lichter P (1996). High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood 88:1437-1444.
5. Butler LM, Zhou X, Xu WS, Scher Hi, Rifkind RA, Marks PA, and Richon VM (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99:11700-11705.
6. Cazzaniga G, Tosi S, Aloisi A, Giudici G, Daniotti M, Pioltelli P, Kearney L, and Biondi A (1999). The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): Molecular cloning of both reciprocal transcripts. Blood 94:4370-4373.
7. Chen KS and DeLuca HF (1994). Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta 1219:26-32.
8. Come SE, Jaffe ES, Andersen JC, Mann RB, Johnson BL, DeVita VT Jr, and Young RC (1980). Non-Hodgkin's lymphomas in leukemic phase: Clinicopathologic correlations. Am J Med 69:667-674.
9. De Jong D, Voetdijk BM, Beverstock GC, van Ommen GJ, Willemze R, and Kluin PM (1988). Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med 318:1373-1378.
10. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, and Raffeld M (1998). Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91:4677-4685.
11. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, Pacini R, Alunni C, Natali-Tanci L, Ugolini B, Sebastiani C, Cattoretti G, Pileri S, Dalla-Favera R, and Stein H (2000). A monoclonal antibody (MUMlp) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95:2084-2092.
12. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, and Honjo T (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027-1034.
13. Fry AM (2002). The Nek2 protein kinase: A novel regulator of centrosome structure. Oncogene 21:6184-6194.
14. Fry AM, Meraldi P, and Nigg EA (1998). A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J 17:470-481.
15. Fry AM, Schultz SJ, Bartek J, and Nigg EA (1995). Substrate specificity and cell cycle regulation of the Nek2 protein kinase, a potential human homolog of the mitotic regulator NIMA of Aspergillus nidulans. J Biol Chem 270:12899-12905.
16. Goff LK, Neat MJ, Crawley CR, Jones L, Jones E, Lister TA, and Gupta RK (2000). The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br J Haematol 111:618-625.
17. Grogan TM, Rangel CS, Rimsza L, Bellamy W, Martel R, McDaniel D, McGraw B, Richards W, Richter L, Rodgers P, Rybski JA, Showalter W, Vela E, and Zeheb R (1995). Kinetic-mode, automated double-labeled immunohistochemistry and in-situ hybridization in diagnostic pathology. Adv Pathol Lab Med 8:79-100.
18. Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus GS, Said JW, and Koeffler HP (2001). Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 98:787-794.
19. Horning SJ (1994). Low-grade lymphoma 1993: State of the art. Ann Oncol 5:23-27.
20. Horning SJ (2000). Follicular lymphoma: Have we made any progress? Ann Oncol 11:23-27.
21. Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, Offit K, and Chaganti RS (1996). REL protooncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 87:25-29.
22. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, Lynch JC, Armitage JO, Warnke RA, Alizadeh AA, Lossos IS, Levy R, and Chan WC (2002). The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99:2285-2290.
23. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, Chaganti RS, and Dalla-Favera R (1997). Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17:226-230.
24. Iijima Y, Ito T, Oikawa T, Eguchi M, Eguchi-Ishimae M, Kamada N, Kishi K, Asano S, Sakaki Y, and Sato Y (2000). A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25; p13) translocation. Blood 95:2126-2131.
25. Ishida Y, Agata Y, Shibahara K, and Honjo T (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887-3895.
26. Jaffe ES, Banks PM, Nathwani B, Said J, and Swerdlow SH (2002). Recommendations for the reporting of lymphoid neoplasms. A report from the Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 33:1064-1068.
27. Johansson B, Mertens F, and Mitelman F (1995). Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood 86: 3905-3914.
28. Joos S, Otano-Joos MI, Ziegler S, Bruderlein S, du Manoir S, Bentz M, Moller P, and Lichter P (1996). Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87:1571-1578.
29. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG, and Choi I (2000). Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164:6287-6295.
30. Kaback DB and Feldberg LR (1985). Saccharomyces cerevisiae exhibits a sporulation-specific temporal pattern of transcript accumulation. Mol Cell Biol 5:751-761.
31. Knutsen T (1997). Cytogenetic mechanisms in the pathogenesis and progression of follicular lymphoma. Cancer Surv 30:163-192.
32. Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, Urbanski SJ, Grogan T, Marquez LA, and Janowska-Wieczorek A (1999). Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant nonHodgkin's lymphomas. Blood 94:2080-2089.
33. Kossakowska AE, Urbanski SJ, Watson A, Hayden LJ, and Edwards DR (1993). Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res 5:19-28.
34. Kruh GD, King CR, Kraus MH, Popescu NC, Amsbaugh SC, McBride WO, and Aaronson SA (1986). A novel human gene closely related to the abl proto-oncogene. Science 234: 1545-1548.
35. Kruh GD, Perego R, Miki T, and Aaronson SA (1990). The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases. Proc Natl Acad Sci USA 87:5802-5806.
36. Kubota T, Miyauchi M, Miura K, Hirokawa G, Awaya A, Miyasaka N, Kurosawa Y, Kanai Y, and Maruyama K (1998). Upregulation of nucleobindin expression in human-activated lymphocytes and non-Hodgkin's lymphoma. Pathol Int 48: 22-28.
37. Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen GJ, Schuuring E, and Kluin PM (1995). Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 85:2528-2536.
38. Lin P, Fischer T, Weiss T, and Farquhar MG (2000). Calnuc, an EF-hand Ca(2+) binding protein, specifically interacts with the C-terminal alpha5-helix of G(alpha)i3. Proc Natl Acad Sci USA 97:674-679.
39. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, and Dalla-Favera R (1993). p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82: 2289-2295.
40. Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, Oefner PJ, Brown PO, Botstein D, and Levy R (2002). Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 99:8886-8891.
41. Masutani H and Yodoi J (2002). Thioredoxin: Overview. Methods Enzymol 347:279-286.
42. Matolcsy A, Casali P, Warnke RA, and Knowles DM (1996). Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 88:3937-3944.
43. Matolcsy A, Schattner EJ, Knowles DM, and Casali P (1999). Clonal evolution of B cells in transformation from low- to high-grade lymphoma. Eur J Immunol 29:1253-1264.
44. McDonnell TJ and Korsmeyer SJ (1991). Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349:254-256.
45. Miura K, Titani K, Kurosawa Y, and Kanai Y (1992). Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure. Biochem Biophys Res Commun 187:375-380.
46. Nishimura H, Nose M, Hiai H, Minato N, and Honjo T (1999). Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-151.
47. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, and Honjo T (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319-322.
48. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, and Yodoi J (1999). Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274:21645-21650.
49. Nomdedeu JF, Baiget M, Gaidano G, Estivill C, Lasa A, Rubiol E, Mateu R, Bordes R, Brunet S, Saglio G, and Soler J (1998). p53 mutation in a case of blastic transformation of follicular lymphoma with double bcl-2 rearrangement (MBR and VCR). Leuk Lymphoma 29:595-605.
50. Okuda K, Weisberg E, Gilliland DG, and Griffin JD (2001). ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440-2448.
51. Ottensmeier CH, Thompsett AR, Zhu D, Wilkins BS, Sweetenham JW, and Stevenson FK (1998). Analysis of VH genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression. Blood 91:4292-4299.
52. Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL, Montserrat E, Cardesa A, and Campo E (1998). p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 91:2977-2984.
53. Primig M, Williams RM, Winzeler EA, Tevzadze GG, Conway AR, Hwang SY, Davis RW, and Esposito RE (2000). The core meiotic transcriptome in budding yeasts. Nat Genet 26:415-423.
54. Rajeevan MS, Vernon SD, Taysavang N, and Unger ER (2001). Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR. J Mol Diagn 3:26-31.
55. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC, and Chaganti RS (1998). Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 92:234-240.
56. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, and Raffeld M (1993). p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994-2004.
57. Stamatopoulos K, Kosmas C, Belessi C, Stavroyianni N, Kyriazopoulos P, and Papadaki T (2000). Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today 21:298-305.
58. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MA, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, et al. (1995). Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85:893-901.
59. Strasser A, Harris AW, Bath ML, and Cory S (1990). Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331-333.
60. Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A, Monconduit M, and Bastard C (1994). Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84:1043-1049.
61. Toledano MB and Leonard WJ (1991). Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA 88:4328-4332.
62. Traweek ST, Liu J, Johnson RM, Winberg CD, and Rappaport H (1993). High-grade transformation of chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma: Genotypic confirmation of clonal identity. Am J Clin Pathol 100: 519-526.
63. Tsuboi K, lida S, Inagaki H, Kato M, Hayami Y, Hanamura I, Miura K, Harada S, Kikuchi M, Komatsu H, Banno S, Wakita A, Nakamura S, Eimoto T, and Ueda R (2000). MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 14:449-456.
64. Wai DH, Schaefer KL, Schramm A, Korsching E, Van Valen F, Ozaki T, Boecker W, Schweigerer L, Dockhorn-Dworniczak B, and Poremba C (2002). Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol 20:441-451.
65. Weiss LM and Warnke RA (1985). Follicular lymphoma with blastic conversion: A report of two cases with confirmation by immunoperoxidase studies on bone marrow sections. Am J Clin Pathol 83:681-686.
66. Wellmann A, Thieblemont C, Pittaluga S, Sakai A, Jaffe ES, Siebert P, and Raffeld M (2000). Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96:398-404.
67. Yano T, Jaffe ES, Longo DL, and Raffeld M (1992). MYC rearrangements in histologically progressed follicular lymphomas. Blood 80:758-767.
68. Yuen AR, Kamel OW, Halpern J, and Horning SJ (1995). Long-term survival after histologic transformation of lowgrade follicular lymphoma. J Clin Oncol 13:1726-1733.
69. Zelenetz AD, Chen TT, and Levy R (1991). Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. J Exp Med 173:197-207.